

# **Supporting Information**

## **Genome Mining Discovery of a New Benzazepine Alkaloid Pseudofisnin A from the Marine Fungus *Neosartorya pseudofischeri* F27-1**

Xiao-Xin Xue<sup>1</sup>, Lin Chen<sup>1</sup>, and Man-Cheng Tang<sup>1,2,\*</sup>

<sup>1</sup> State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China

<sup>2</sup> Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai 200240, China

\*Correspondence: tangmc@sjtu.edu.cn

## Table of contents

<b>SUPPLEMENTART TABLES.....</b>	<b>S3</b>
Table S1. Bioinformatics analysis of the <i>pse</i> gene cluster. ....	S3
Table S2. Primers used in this study. ....	S3
Table S3. Plasmids used in this study. ....	S4
Table S4. NMR data of nanangelenin B ( <b>3</b> ) in DMSO- <i>d</i> <sub>6</sub> . ....	S5
Table S5. NMR data of pseudofisinin B ( <b>2</b> ) in CDCl <sub>3</sub> .....	S6
Table S6. NMR data of pseudofisinin A ( <b>1</b> ) in CDCl <sub>3</sub> . ....	S7
<b>SUPPLEMENTART FIGURES.....</b>	<b>S8</b>
Figure S1. SDS-PAGE analysis of purified PseC. ....	S8
Figure S2. Kinetic analysis of the methylation reaction catalyzed by PseC. ....	S8
Figure S3. HR-ESIMS of (a) pseudofisinin B and (b) pseudofisinin A. ....	S9
Figure S4. <sup>1</sup> H NMR spectrum of nanangelenin B ( <b>3</b> ) in DMSO- <i>d</i> <sub>6</sub> .....	S100
Figure S5. <sup>13</sup> C NMR spectrum of nanangelenin B ( <b>3</b> ) in DMSO- <i>d</i> <sub>6</sub> .....	S100
Figure S6. DEPT 135 spectrum of nanangelenin B ( <b>3</b> ) in DMSO- <i>d</i> <sub>6</sub> .....	S111
Figure S7. <sup>1</sup> H NMR spectrum of pseudofisinin B ( <b>2</b> ) in CDCl <sub>3</sub> .....	S111
Figure S8. <sup>13</sup> C NMR spectrum of pseudofisinin B ( <b>2</b> ) in CDCl <sub>3</sub> .....	S122
Figure S9. DEPT 135 spectrum of pseudofisinin B ( <b>2</b> ) in CDCl <sub>3</sub> .....	S122
Figure S10. COSY spectrum of pseudofisinin B ( <b>2</b> ) in CDCl <sub>3</sub> .....	S133
Figure S11. HSQC spectrum of pseudofisinin B ( <b>2</b> ) in CDCl <sub>3</sub> .....	S133
Figure S12. HMBC spectrum of pseudofisinin B ( <b>2</b> ) in CDCl <sub>3</sub> .....	S134
Figure S13. <sup>1</sup> H NMR spectrum of pseudofisinin A ( <b>1</b> ) in CDCl <sub>3</sub> .....	S134
Figure S14. <sup>13</sup> C NMR spectrum of pseudofisinin A ( <b>1</b> ) in CDCl <sub>3</sub> .....	S135
Figure S15. DEPT 135 spectrum of pseudofisinin A ( <b>1</b> ) in CDCl <sub>3</sub> .....	S135
Figure S16. COSY spectrum of pseudofisinin A ( <b>1</b> ) in CDCl <sub>3</sub> .....	S136
Figure S17. HSQC spectrum of pseudofisinin A ( <b>1</b> ) in CDCl <sub>3</sub> .....	S136
Figure S18. HMBC spectrum of pseudofisinin A ( <b>1</b> ) in CDCl <sub>3</sub> .....	S13

## SUPPLEMENTART TABLES

**Table S1.** Bioinformatics analysis of the *pse* gene cluster.

Genes	Proteins	Gene size (bp/aa)	Putative Function
<i>pseA</i> (XP_026618556)	PseA	7523/2381	NRPS
<i>pseB</i> (XP_026618558)	PseB	1315/415	Indoleamine 2,3-dioxygenase
<i>pseC</i> (XP_026618557)	PseC	1407/384	Methyltransferase
<i>pseD</i> (XP_026618560)	PseD	1236 /411	flavine-dependent monooxygenase
<i>pseE</i> (XP_026618559)	PseE	879/292	Hypothetical protein
<i>pseF</i> (XP_026618554)	PseF	387/128	Blasticidin-S deaminase
<i>pseG</i> (XP_026618553)	PseG	1185/394	UbiH type hydroxylase


**Table S2.** Primers used in this study.

Primer name	Primer sequence (5'→3')
AmyB_5'- <i>pseA</i> -F	CCCTTCTCTAACATAAAACCCCCACAGAAGGCATTATGGACAAC TGTAAGATGCCG
<i>pseA</i> -1-R	CAGACCCTCTGCACGTGATAAG
<i>pseA</i> -2-F	CATCCAAGACGCATATCCTTG
<i>pseA</i> -2-R	AATATCGTCACACACCCACGAC
<i>pseA</i> -3-F	CCATCATCGCATCTACAAGACG
<i>glaA</i> - <i>pseA</i> -R	CGACCAGTCGGAAGATCAGGCTTGGCCACTGAGGAAGATG
<i>pseA</i> - <i>glaA</i> -F	CATCTCCTCAGTGGACCAAGCCTGATCTTCCGAACGGTCG
<i>pseF</i> - <i>glaA</i> -R	CCTCGGGGGTGAGGGGCATTGCTGAGGTGTAATGATGCTG
<i>glaA</i> - <i>pseF</i> -F	CAGCATCATTACACCTCAGCAATGCCCTCACCCCGAGG
<i>pseF</i> -pYTP-R	GTGATGAGACCCAACAACCATGATACCAGGGATTGTTCTTCTTG AGCGTTGCACAG
<i>glaA</i> - <i>pseD</i> -F	CCTGAGCTTCATCCCCAGCATCATTACACCTCAGCAATGACGGTCA TCGACCAGGTC
AmyB- <i>pseD</i> _5'-R	GCTCGTTGGCACCTTAATCTCTGGAAATGGACATACGCTC
<i>pseD</i> -AmyB_5'-F	GAGCGTATGCCATTCCAGAGAGATTAAAGGTGCCAACGAGC
<i>pseB</i> -AmyB_5'-R	GATCCCTCCGAGTCCTGGCATAATGCCTCTGTGGGGTTATTG
AmyB_5'- <i>pseB</i> -F	CAATAAACCCCACAGAAGGCATTATGCCAGGACTGGAGGGATC
<i>pseB</i> -pYTU-R	ACAGTGGAGGACATACCGTAATTCTGGCATTGGTCACGAT GCCATTGATGTG
<i>gpdA</i> - <i>pseE</i> -F	ctaaccattacccggccacatagacacatctaaacaATGTCGACAACCTCCACCAAG
AmyB_5'- <i>pseE</i> -R	GCTCGTTGGCACCTTAATCAGCCAGCCTGCTGAGTTGAAG
<i>pseE</i> -AmyB_5'-F	CTTCAACTCAAGCAGGCTGGCTGATTAAAGGTGCCAACGAGC
<i>pseC</i> -AmyB_5'-R	CTGGCTAATTCCCGTGTCAATAATGCCTCTGTGGGGTTATTG
AmyB_5'- <i>pseC</i> -F	CAATAAACCCCACAGAAGGCATTATGACACGGAAATTAGCCAG
<i>glaA</i> - <i>pseC</i> -F	CGACCAGTCGGAAGATCAGGAGAACATATGGCATGGCTGC
<i>pseC</i> - <i>glaA</i> -F	GCAGCCATGACCATATGTTCTCCTGATCTCCGAACGGTCG
<i>pseG</i> - <i>glaA</i> -R	CCTCGGGGGTGAGGGGCATTGCTGAGGTGTAATGATGCTG

<i>glaA-pseG-F</i>	CCAGCATCATTACACCTCAGCAATGCCCAACCCGAATCG
<i>pseG-pYTR-R</i>	CTAAAGGGTATCATCGAAAGGGAGTCATCCAATTGTTGATCTGCG GTGAGAGATTG
<i>pseA--pYTP-R</i>	TGATGAGACCCAACAACCATGATACCAGGGATTCTGGTCCAC TGAGGAAGATG
<i>glaA-pseB-F</i>	CTGAGCTTCATCCCCAGCATCATTACACCTCAGCAATGCCAGGACT CGGAGGGATC
<i>pseB-pYTR-R</i>	ACAGTGGAGGACATACCGTAATTTCTGGCATTGGTCGACGAT GCCATTGATGTG
<i>gpdA-pseC-F</i>	taaccattacccggccatagacacatctaaacaATGACACGGAAATTAGCCAG
<i>pseC-pYTU-R</i>	CTAAAGGGTATCATCGAAAGGGAGTCATCCAATTAGAAACATATG GTCATGGCTGC
<i>pET28a-pseC-F</i>	GTGCCGCGCGGCAGCCATATGATGACACGGAAATTAGCCAG
<i>pseC-1-R</i>	CCTCCCGAACGACATCTGAGTAGGGACCTTGAAGCC
<i>pseC-2-F</i>	GGCTTCAAGGTCCCTACTCAGATGTGCGTTGCGGGAGG
<i>pseC-2-R</i>	GTCATGAGACCAACATCGGACATATGATGGACCCACGCGCCTC
<i>pseC-3-F</i>	GAGGCGCGTGGTCCATCATATGTCCGATGTTGGTCTCATGAC
<i>pseC-3-R</i>	GAAAGCGTAGAAAGATTGGTCCGTACGCCATCTGAAACG
<i>pseC-4-F</i>	CGTTTCAGATGGCGTACCGGACGGACCAATCTTCTACGCTTC
<i>pseC-4-R</i>	CCTAGGATGGTGCAACAGTCCTCTGAAGTATGGTCCATCAGGATG
<i>pseC-5-F</i>	CATCCTGATGGACCATACTTCAGAGGACTGTTGCACCACCTAGG
<i>pET28a-pseC-R</i>	ACGGAGCTCGAATTGGATCCCTAGCCCACCTCTTCAGAGC

**Table S3.** Plasmids used in this study.

Plasmids	Vector	Genes
pXXX1-1	pYTP	AmyB_5'- <i>pseA</i> ; <i>glaA-pseF</i>
pXXX1-2	pYTU	AmyB_5'- <i>pseB</i> ; <i>glaA-pseD</i>
pXXX1-3	pYTR	GpdA- <i>pseE</i> ; AmyB_5'- <i>pseC</i> ; <i>GlaA-pseG</i>
pXXX1-4	pYTP	AmyB_5'- <i>pseA</i>
pXXX1-5	pYTU	<i>glaA-pseB</i>
pXXX1-6	pYTR	GpdA- <i>pseC</i>
pXXX1-7	pET28a	T7p-N-his- <i>pseC-T7t</i>


**Table S4.** NMR data of nanangelenin B (**3**) in DMSO-*d*<sub>6</sub>.<sup>1</sup>H NMR spectrum (600 MHz), <sup>13</sup>C NMR spectrum (150 MHz)

No.	$\delta_{\text{H}}$ ( <i>J</i> in Hz)	$\delta_{\text{C}}$ , type
1	10.36, s	
2		137.7, C
3	7.26, t (7.8)	124.3, CH
4	7.61, m	134.2, CH
5	7.19, d (8.1)	122.2, CH
6	7.75, dd (7.9, 1.7)	130.0, CH
7		128.4, C
8		197.8, C
9	3.02, dd (18.7, 2.7) 3.26, dd (18.7, 13.3)	45.8, CH <sub>2</sub>
10	5.00,ddd (13.3, 7.5, 2.7)	46.1, CH
11		171.2, C
12	8.42, d (7.4)	
13		168.6, C
14		113.9, C
15		149.7, C
16	6.70, d (8.2)	116.4, CH
17	7.16, m	132.1, CH
18	6.54, t (7.5)	114.6, CH
19	7.58, dd (8.0, 1.6)	128.4, CH
20	6.36, brs	

“m” means overlapped or multiplet with other signals.

The NMR data of 1 is identical to the data reported in *J. Am. Chem. Soc.* 2020, 142(15), 7145-7152.


**Table S5.** NMR data of pseudofisnin B (**2**) in  $\text{CDCl}_3$ .  
 $^1\text{H}$  NMR spectrum (600 MHz),  $^{13}\text{C}$  NMR spectrum (150 MHz)



No.	$\delta_{\text{H}}$ ( $J$ in Hz)	$\delta_{\text{C}}$ , type
1	7.70, s	
2		135.4, C
3	7.00, d (8.0)	122.1, CH
4	7.56, t (7.7)	134.4, CH
5	7.32, t (7.7)	126.2, CH
6	7.93, d (8.0)	131.2, CH
7		129.8, C
8		196.6, C
9	3.04, dd (18.9, 12.9) 3.44, m	47.3, $\text{CH}_2$
10	5.20, m	46.5, CH
11		171.7, C
12		
13		169.0, C
14		113.5, C
15		150.9, C
16	6.67, d (8.47)	111.3, CH
17	7.35, t (7.70)	133.5, CH
18	6.63, t (7.70)	114.6, CH
19	7.49, d (8.07)	127.7, CH
20	6.80, s	
21	2.85, d (4.30)	29.6, $\text{CH}_3$

“m” means overlapped or multiplet with other signals.

**Table S6.** NMR data of pseudofisnin A (**1**) in  $\text{CDCl}_3$ .  
 $^1\text{H}$  NMR spectrum (600 MHz),  $^{13}\text{C}$  NMR spectrum (150 MHz)




No.	$\delta_{\text{H}}$ ( $J$ in Hz)	$\delta_{\text{C}}$ , type
1	7.69, s	
2		135.7, C
3	6.99, d (8.0)	122.0, CH
4	7.54, t (7.7)	134.3, CH
5	7.31, t (7.7)	126.0, CH
6	7.93, d (8.0)	131.1, CH
7		130.1, C
8		197.5, C
9	3.07, dd (19.0, 12.9) 3.47, dd (19.0, 3.2)	47.4, $\text{CH}_2$
10	5.39, m	47.0, CH
11		171.9, C
12	11.06, d (6.30)	
13		165.8, C
14		126.7, C
15		153.0, C
16	7.27, d (8.0)	120.3, CH
17	7.45, t (7.7)	132.4, CH
18	7.19, t (7.7)	124.3, CH
19	8.11, d (7.9)	131.4, CH
20		
21	2.79, s	45.4, $\text{CH}_3$
22	2.79, s	45.4, $\text{CH}_3$

“m” means overlapped or multiplet with other signals.

## SUPPLEMENTART FIGURES


**Figure S1.** SDS-PAGE analysis of purified PseC.

Left lane: protein marker; Right lane: the purified PseC (46.8 kDa).




**Figure S2.** Kinetic analysis of the methylation reaction catalyzed by PseC.


(a) nanangelenin B (**3**) as the substrate; (b) pseudofisnin B (**2**) as the substrate.




**Figure S3.** HR-ESIMS data of (a) pseudofisnin B and (b) pseudofisnin A.




**Figure S4.**  $^1\text{H}$  NMR spectrum of nanangelenin B (**3**) in  $\text{DMSO}-d_6$ .




**Figure S5.**  $^{13}\text{C}$  NMR spectrum of nanangelenin B (**3**) in  $\text{DMSO}-d_6$ .




**Figure S6.** DEPT 135 spectrum of nanangelenin B (**3**) in DMSO-*d*<sub>6</sub>.




**Figure S7.** <sup>1</sup>H NMR spectrum of pseudofisinin B (**2**) in CDCl<sub>3</sub>.




**Figure S8.**  $^{13}\text{C}$  NMR spectrum of pseudofisinin B (**2**) in  $\text{CDCl}_3$ .




**Figure S9.** DEPT 135 spectrum of pseudofisinin B (**2**) in  $\text{CDCl}_3$ .




**Figure S10.** COSY spectrum of pseudofisnin B (**2**) in  $\text{CDCl}_3$ .




**Figure S11.** HSQC spectrum of pseudofisnin B (**2**) in  $\text{CDCl}_3$ .




**Figure S12.** HMBC spectrum of pseudofisinin B (**2**) in  $\text{CDCl}_3$ .




**Figure S13.**  $^1\text{H}$  NMR spectrum of pseudofisinin A (**1**) in  $\text{CDCl}_3$ .




**Figure S14.**  $^{13}\text{C}$  NMR spectrum of pseudofisinin A (**1**) in  $\text{CDCl}_3$ .




**Figure S15.** DEPT 135 spectrum of pseudofisinin A (**1**) in  $\text{CDCl}_3$ .



**Figure S16.** COSY spectrum of pseudofisnin A (**1**) in  $\text{CDCl}_3$ .



**Figure S17.** HSQC spectrum of pseudofisnin A (**1**) in  $\text{CDCl}_3$ .



**Figure S18.** HMBC spectrum of pseudofisinin A (**1**) in  $\text{CDCl}_3$ .

